“Given there is not any new information to review,” Coherus BioSciences continues to anticipate approval from the “resource-constrained” US Food and Drug Administration for the company’s version of Amgen’s Neulasta (pegfilgrastim) Onpro on-body injector device using Coherus’ Udenyca (pegfilgrastim-cbqv) biosimilar “this year or in the early part of 2024.”
While pivoting towards a more novel biologics strategy, Coherus’ plotted return to growth for Udenyca is important in the next couple of years given that the firm concedes it will not see significant growth for its adalimumab biosimilar,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?